EPIDIOLEX® (cannabidiol) has broad-spectrum efficacy, significantly reducing multiple seizure types in TSC, LGS, and Dravet syndrome
Efficacy proven across 3 of the most difficult-to-treat epilepsies1-3
Demonstrated significant reductions in TSC-associated seizures, including both partial-onset* and generalized seizures; drop/total seizures in LGS; and convulsive seizures in Dravet syndrome
Studied in patients on a wide range of concomitant treatments, EPIDIOLEX can be used as a monotherapy or with other AEDs
Sustained effects up to 3 years in open-label extensions in LGS and Dravet syndrome4,5
*Partial-onset seizures (focal) included simple partial seizures (focal motor seizure), complex partial seizures (focal impaired), and secondary generalized tonic-clonic seizures (focal to bilateral tonic-clonic).6
The only medication indicated to treat seizures associated with TSC, LGS, and Dravet syndrome in patients 1 year and older
Structurally distinct from other AEDs
Can be prescribed in adults and children as early as 1 year of age across 3 indications
Cammy, age 3 | EPIDIOLEX patient living with TSC
Bobby, age 41 | EPIDIOLEX patient living with Dravet syndrome
The first and only FDA-approved cannabidiol
Quality standards for stability and consistency
Highly controlled manufacturing7
No longer a federally scheduled drug
Eligible for insurance coverage
Derived from pesticide- and contaminant-free plants7
Efficacy, safety, and dosing established across multiple controlled studies7
More patients like yours are discovering seizure reductions with EPIDIOLEX
Since approval, more than 35,000 patients in the United States have been treated with EPIDIOLEX by over 3,000 prescribers7,8
EPIDIOLEX was studied in over 900 patients with LGS, Dravet syndrome, or TSC—making up the largest controlled clinical trial program for an AED in these conditions to date7,9,10†
†There was a second randomized controlled trial in 199 patients with Dravet syndrome that has been completed since its original approval.9
Designed with your patients in mind, EPIDIOLEX offers flexible dosing for tolerability and response optimization
